Ranbaxy Laboratories Ltd., India's biggest drugmaker, has received the US Food and Drug Administration's (USFDA) approval for selling cyclobenzaprine hydrochloride tablets in different strengths in the US markets.

Cyclobenzaprine HCl Tablets USP are indicated as adjuncts to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

The company has got the approval of USFDA to launch cyclobenzaprine hydrochloride in 5mg, 7.5 mg and 10 mg strengths.

ecently, Ranbaxy Laboratories has signed a drug discovery and development agreement with global pharmaceutical major Merck & Co.
The strategic product development agreement calls for joint research to develop clinically validated anti-bacterial and anti-fungal drug candidates.